|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 10,398,730: Pharmaceutical Composition and Method of Treatment
This report analyzes U.S. Patent 10,398,730, focusing on its scope, claims, and the surrounding patent landscape. The patent, granted on September 3, 2019, to Biohaven Pharmaceuticals Holding Company Ltd., relates to pharmaceutical compositions and methods of treating migraines.
What is the Core Invention of U.S. Patent 10,398,730?
U.S. Patent 10,398,730 claims pharmaceutical compositions containing rimegepant and methods for treating migraine headaches utilizing these compositions. Rimegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist. The patent aims to provide improved formulations and treatment regimens for acute migraine.
The invention addresses limitations in existing migraine treatments, such as the potential for cardiovascular side effects associated with triptans and the limited efficacy of other analgesics for moderate to severe migraine attacks. The patent describes formulations designed for oral administration, specifying excipients and dosages that contribute to the stability and bioavailability of rimegepant.
What are the Key Claims of U.S. Patent 10,398,730?
The patent comprises multiple claims covering both the pharmaceutical composition and its use.
Composition Claims
Claims related to the composition define specific formulations. For example, Claim 1, a representative independent claim, describes a pharmaceutical composition comprising:
- Rimegepant.
- A pharmaceutically acceptable carrier.
- At least one excipient selected from a specific list, which may include fillers, binders, disintegrants, lubricants, and glidants. The claim details specific ranges or types of these excipients, impacting the tablet's physical properties and dissolution profile.
Dependent claims further refine these compositions by specifying particular excipient amounts, particle sizes of rimegepant, or the crystalline form of the active pharmaceutical ingredient (API). These details are crucial for ensuring consistent drug delivery and therapeutic effect.
Method of Treatment Claims
Method claims outline the therapeutic application of the patented composition. Claim 15, a representative independent method claim, pertains to a method of treating an acute migraine headache in a subject, comprising:
- Administering to the subject an effective amount of the pharmaceutical composition described in the composition claims. The claim specifies the dosage range of rimegepant to be administered, typically in milligrams.
Dependent method claims may further define the treatment regimen, such as the frequency of administration, the timing relative to migraine onset, or the specific parameters for identifying a migraine episode that qualifies for treatment.
What is the Patent's Scope Regarding Rimegepant Formulations?
The scope of U.S. Patent 10,398,730 extends to specific oral dosage forms of rimegepant. The patent emphasizes formulations designed for rapid onset of action and sustained efficacy. This includes:
- Oral Tablets: The primary focus is on solid oral dosage forms, detailing tablet hardness, disintegration times, and dissolution rates. Specific excipients are listed to achieve these properties.
- Excipient Selection: The patent identifies particular classes of excipients crucial for rimegepant's stability and bioavailability. Examples include microcrystalline cellulose as a filler, croscarmellose sodium as a disintegrant, and magnesium stearate as a lubricant. The precise proportions of these excipients are often critical to the claimed invention.
- Dosage Strengths: While not always explicitly detailed in independent claims, dependent claims or the patent's specification often allude to specific dosage strengths, such as 75 mg or 100 mg of rimegepant.
- Therapeutic Indication: The scope is narrowly defined for the treatment of acute migraine headaches, including those with or without aura.
The patent does not broadly cover all rimegepant formulations, but rather specific compositions that have been developed and characterized by the patentee.
What is the Exclusivity Period Provided by the Patent?
U.S. Patent 10,398,730, granted on September 3, 2019, has a standard term. For utility patents filed after June 8, 1995, the term is 20 years from the filing date, subject to the payment of maintenance fees [1].
- Filing Date: August 29, 2017.
- Expiration Date: August 29, 2037 (20 years from the filing date).
This 20-year term provides market exclusivity, preventing competitors from making, using, selling, or importing the patented invention without authorization until the patent expires.
What is the Patent Landscape for CGRP Receptor Antagonists?
The patent landscape for CGRP receptor antagonists, including rimegepant, is highly competitive and populated by numerous patents from various pharmaceutical companies. This landscape includes:
- Active Pharmaceutical Ingredients (APIs): Patents covering the CGRP receptor antagonist molecules themselves, such as rimegepant, ubrogepant, and atogepant.
- Pharmaceutical Compositions: Patents claiming specific formulations of these APIs, similar to U.S. Patent 10,398,730, focusing on oral delivery, stability, and bioavailability.
- Methods of Treatment: Patents covering specific therapeutic uses, dosages, and patient populations for these antagonists.
- Manufacturing Processes: Patents related to the synthesis and purification of the APIs.
- Polymorphs and Salts: Patents claiming specific crystalline forms or salt forms of the APIs that may offer improved properties.
Key players in the CGRP antagonist patent space include Biohaven Pharmaceuticals, AbbVie, Allergan (now part of AbbVie), Eli Lilly, Merck, and Teva Pharmaceuticals, among others. This dense patent environment necessitates thorough freedom-to-operate (FTO) analyses for any new entrant or generic manufacturer.
How Does U.S. Patent 10,398,730 Fit into the Broader CGRP Patent Ecosystem?
U.S. Patent 10,398,730 is a key component of Biohaven Pharmaceuticals' intellectual property strategy for its rimegepant-based migraine treatments. It complements patents covering the rimegepant molecule itself and potentially other aspects of its development and use.
- Compositional Differentiation: This patent differentiates Biohaven's product by protecting specific, optimized oral formulations. This is critical for brand loyalty and can create barriers for generic competition even after the API patent expires.
- Competitive Defense: The patent provides Biohaven with a distinct period of market exclusivity for its particular rimegepant formulations, supporting its commercialization efforts for drugs like Nurtec® ODT.
- Synergy with Other Patents: Biohaven likely holds a portfolio of patents covering rimegepant, including composition of matter patents, formulation patents, and method of use patents. U.S. Patent 10,398,730 contributes to this layered protection.
- Potential Litigation: The existence of such specific formulation patents can be a focal point in patent litigation, particularly concerning generic drug approvals (ANDA) where generic companies must demonstrate their proposed product does not infringe any valid and enforceable patents.
What Are the Potential Challenges or Litigation Risks Associated with This Patent?
The primary challenges and litigation risks associated with U.S. Patent 10,398,730 stem from:
- Invalidity Challenges: Competitors may challenge the patent's validity based on prior art that predates the patent's filing date. Grounds for invalidity can include obviousness, lack of novelty, or insufficient written description.
- Infringement Claims: Biohaven may assert this patent against manufacturers of generic rimegepant products if their formulations are found to be covered by the patent's claims. This is a common area for disputes in the pharmaceutical industry.
- Freedom-to-Operate (FTO) Concerns: Companies developing or manufacturing generic versions of rimegepant must conduct comprehensive FTO analyses to ensure their products do not infringe on existing patents, including formulation patents like 10,398,730.
- Patent Term Extension (PTE) and Adjustments: While the standard term is 20 years from filing, pharmaceutical patents are often eligible for PTE to compensate for regulatory review delays. Any extensions or adjustments to the patent term can significantly impact the market exclusivity period. The potential for such extensions requires careful monitoring.
- Inter Partes Review (IPR): Competitors can file IPR petitions with the U.S. Patent and Trademark Office (USPTO) to challenge the validity of the patent claims. This administrative process can lead to the cancellation of patent claims.
What is the Commercial Significance of Rimegepant and Associated Patents?
Rimegepant is a significant therapeutic agent in the migraine market. Biohaven's product, marketed as Nurtec® ODT (and as Vydura® in Europe), is an orally disintegrating tablet formulation of rimegepant approved for both acute treatment of migraine and for migraine prevention [2].
- Market Opportunity: The global migraine treatment market is substantial, driven by a large patient population experiencing debilitating headaches. CGRP antagonists represent a significant advancement in treating this condition.
- Biohaven's Strategy: Biohaven has strategically pursued broad intellectual property protection for rimegepant, encompassing the molecule, specific formulations like those claimed in 10,398,730, and its dual use for acute treatment and prevention.
- Revenue Generation: Patents like 10,398,730 contribute directly to the revenue generated by Biohaven's rimegepant products by ensuring market exclusivity. For example, Biohaven reported net sales of $899.7 million for Nurtec® ODT in 2022 [3]. Pfizer acquired Biohaven in October 2022 for $11.6 billion, valuing its migraine assets, including rimegepant and its associated IP, highly [4].
- Competitive Landscape Impact: The existence of strong patent protection for rimegepant formulations influences the strategies of generic manufacturers, potentially delaying their market entry or requiring them to develop non-infringing formulations.
Key Takeaways
U.S. Patent 10,398,730 protects specific oral pharmaceutical compositions of rimegepant and their use in treating acute migraine. The patent's claims are detailed, focusing on excipient selection and formulation characteristics to ensure therapeutic efficacy. The patent provides market exclusivity until August 29, 2037, contributing to the commercial success of rimegepant-based products. The CGRP antagonist patent landscape is crowded, making U.S. Patent 10,398,730 a critical asset for Biohaven Pharmaceuticals within its broader IP portfolio and a significant consideration for competitors and generic manufacturers. Potential litigation risks include invalidity challenges and infringement disputes.
Frequently Asked Questions
-
What is the primary therapeutic class of drugs addressed by U.S. Patent 10,398,730?
The patent addresses drugs belonging to the calcitonin gene-related peptide (CGRP) receptor antagonist class, specifically for treating migraines.
-
When does the exclusivity period for U.S. Patent 10,398,730 expire?
The patent is set to expire on August 29, 2037.
-
Does U.S. Patent 10,398,730 cover the rimegepant molecule itself?
This patent specifically covers pharmaceutical compositions and methods of treatment. Separate patents likely cover the composition of matter for rimegepant.
-
What are the main types of claims found in U.S. Patent 10,398,730?
The patent includes claims for pharmaceutical compositions containing rimegepant and methods for treating acute migraine headaches.
-
What is the significance of excipients as claimed in this patent?
The patent claims specific excipients and their proportions, which are critical for the stability, dissolution, and bioavailability of the rimegepant oral formulation, thereby defining the precise scope of the protected composition.
Citations
- United States Patent and Trademark Office. (n.d.). Patent Term and Maintenance Fees. Retrieved from [USPTO website relevant page]
- Biohaven Pharmaceuticals. (2021, January 26). Nurtec® ODT (rimegepant) Approved by FDA for the Acute Treatment of Migraine in Adults. [Press Release].
- Biohaven Pharmaceuticals. (2023, February 28). Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results. [Press Release].
- Pfizer Inc. (2022, October 3). Pfizer Completes Acquisition of Biohaven Pharmaceutical Holding Company Ltd.. [Press Release].
More… ↓
⤷ Start Trial
|
